{"schema_version":"1.0","type":"article","title":"【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】","url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.md","lang":"zh-Hant","date":"2026-07-07","publish_at":"2026-07-07T08:49:37+08:00","updated_at":"2026-07-07","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","ADC","PD-1/VEGF","雙特異性抗體","BD","臨床數據","生技投資","腫瘤藥物","製藥巨頭","台灣生技"],"summary":"sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。","key_points":[],"facts":[],"sections":["01｜sigvotatug vedotin 失利，問題不只是單一試驗","02｜Seagen 收購案的核心，是輝瑞錯過 PD-1 黃金十年後的補課","03｜ADC 單藥越來越難，聯合療法才是下一個戰場","04｜為什麼是 PD-1/VEGF？因為它想同時碰免疫與血管生成","05｜從 ClinicalTrials.gov 看，輝瑞已經把 PF-08634404 鋪得很廣","06｜輝瑞真正想複製的，可能是 PADCEV + Keytruda 的邏輯","07｜台灣投資人可以怎麼看？不要只看 ADC 題材，要看三種能力","08｜這場賭局真正的風險：雙抗不是萬靈丹，ADC 也不是免死金牌","結語｜輝瑞不是只押 ADC，而是在重建自己的腫瘤底座"],"references":[{"title":"Pfizer, [Pfizer Completes Acquisition of Seagen](), 2023/12/14。","source":"","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen"},{"title":"Pfizer, [Pfizer Completes Licensing Agreement with 3SBio](), 2025/07/24。","source":"","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio"},{"title":"ClinicalTrials.gov, [NCT06012435, SGN-B6A versus docetaxel in previously treated NSCLC]()。","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06012435"},{"title":"ClinicalTrials.gov, [NCT06758401, sigvotatug vedotin plus pembrolizumab in PD-L1 high NSCLC]()。","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06758401"},{"title":"ClinicalTrials.gov, [NCT07227298, PF-08634404 combination study in advanced cancers]()。","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07227298"},{"title":"ClinicalTrials.gov, [NCT07222566, PF-08634404 plus chemotherapy in NSCLC]()。","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07222566"},{"title":"ClinicalTrials.gov, [NCT07226999, PF-08634404 in extensive-stage small cell lung cancer]()。","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07226999"},{"title":"ClinicalTrials.gov, [NCT07421700, PF-08634404 plus enfortumab vedotin in urothelial cancer]()。","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07421700"},{"title":"免責聲明：本文僅為產業研究與市場觀察，不構成任何投資建議、買賣建議或個股推薦。生技醫藥投資涉及臨床試驗、法規審查、授權談判、商業化、匯率與資本市場波動等多重風險，投資人應自行判斷並自負盈虧。","source":"","date":"","url":""},{"title":"更多生技醫藥產業研究與公司觀察，歡迎追蹤藥時事官方網站：","source":"","date":"","url":""},{"title":"https://drugnews.com.tw/","source":"","date":"","url":"https://drugnews.com.tw/"}],"images":[{"alt":"Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 1）","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-01.png"},{"alt":"Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 2）","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-02.png"},{"alt":"Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 3）","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-03.png"},{"alt":"Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 4）","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-07）。【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】。https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}